Kailera completes enrollment in three Phase 3 trials of ribupatide for obesity
The KaiNETIC program randomized roughly 4,900 adults across more than 200 sites in eleven countries, with topline data expected in mid-2028.
PR
By Priya Raman · Science Reporter
Sep 30 07:16 ETSource: manilatimes.net
The wire
- 01Kailera Therapeutics said enrollment is complete in KaiNETIC-1 (about 2,500 adults), KaiNETIC-2 (about 1,200 with type 2 diabetes) and KaiNETIC-3 (about 1,200 with BMI 35 or higher), testing weekly ribupatide up to 10 mg over 76 weeks.
- 02Ribupatide is a dual GLP-1/GIP receptor agonist peptide; KaiNETIC-3 includes an open-label semaglutide 2.4 mg comparator arm, giving a head-to-head read against an approved incretin.
- 03Topline results are not expected until mid-2028, so efficacy, tolerability and discontinuation rates remain unknown; the company describes the drug as potentially best-in-class.
From the source
Read at manilatimes.netKailera Therapeutics Announces Completion of Enrollment in KaiNETIC Global Phase 3 Clinical Program of GLP-1/GIP Receptor Dual Agonist Ribupatide Injection
- Ribupatide injection (KAI-9531) aims to address critical need for greater weight loss, especially for people living with a BMI of 35 kg/m ² or higher
